Improving cancer treatment by targeting specific enzymes in immune cells
Targeting ROS enzymes in immunosuppressive myeloid cells to enhance immunotherapy
This study is looking at how specific enzymes in certain immune cells might affect how well cancer treatments work for people with metastatic melanoma, and it aims to find ways to improve those treatments for better results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-10916378 on NIH RePORTER |
What this research studies
This research investigates how certain enzymes in immunosuppressive myeloid cells affect the immune response to cancer therapies, particularly in patients with metastatic melanoma. The study focuses on understanding the role of reactive oxygen species (ROS) produced by these enzymes, which may hinder the effectiveness of immunotherapy. By characterizing these immune cells and their functions, the research aims to enhance the response to existing cancer treatments. Patients may be involved in trials that explore new ways to improve their treatment outcomes based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic melanoma who have not responded to current immunotherapy treatments.
Not a fit: Patients with early-stage melanoma or those who have not undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for patients with metastatic melanoma, potentially increasing their chances of survival.
How similar studies have performed: Previous research has shown promise in targeting immune cell functions to enhance cancer treatment, suggesting that this approach may yield beneficial results.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Liu, Tracy W — West Virginia University
- Study coordinator: Liu, Tracy W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.